Meex RC, Hoy AJ, Mason RM, Martin SD, McGee SL, Bruce CR, Watt MJ. ATGL-mediated triglyceride turnover and the regulation of mitochondrial capacity in skeletal muscle. Am J Physiol Endocrinol Metab 308: E960 -E970, 2015. First published April 7, 2015; doi:10.1152/ajpendo.00598.2014.-Emerging evidence indicates that skeletal muscle lipid droplets are an important control point for intracellular lipid homeostasis and that regulating fatty acid fluxes from lipid droplets might influence mitochondrial capacity. We used pharmacological blockers of the major triglyceride lipases, adipose triglyceride lipase (ATGL) and hormone-sensitive lipase, to show that a large proportion of the fatty acids that are transported into myotubes are trafficked through the intramyocellular triglyceride pool. We next tested whether increasing lipolysis from intramyocellular lipid droplets could activate transcriptional responses to enhance mitochondrial and fatty acid oxidative capacity. ATGL was overexpressed by adenoviral and adenoassociated viral infection in C 2C12 myotubes and the tibialis anterior muscle of C57Bl/6 mice, respectively. ATGL overexpression in C 2C12 myotubes increased lipolysis, which was associated with increased peroxisome proliferator-activated receptor (PPAR)-‫ץ‬ activity, transcriptional upregulation of some PPAR‫ץ‬ target genes, and enhanced mitochondrial capacity. The transcriptional responses were specific to ATGL actions and not a generalized increase in fatty acid flux in the myotubes. Marked ATGL overexpression (20-fold) induced modest molecular changes in the skeletal muscle of mice, but these effects were not sufficient to alter fatty acid oxidation.
adipose triglyceride lipase; lipolysis; fatty acid metabolism LIPOLYSIS INVOLVES THE BREAKDOWN of triglycerides (TAG) stored within intracellular lipid droplets and results in the production of glycerol and fatty acids (FA). In contrast to adipose tissue, where FA liberated during lipolysis can be released into the circulation to provide metabolic substrate for other tissues, there is minimal FA release from skeletal muscle (18, 37) . Instead the FA derived from intramyocellular lipolysis serve as an important local metabolic substrate, particularly during exercise (30, 38, 40) . It has been known for some time that a large proportion of the FA transported from the plasma into skeletal muscle are first trafficked into TAG before they are released for oxidative metabolism (5, 15, 29) . Hence, TAG stored within intracellular lipid droplets form a central pool that regulates the delivery of FA to the intramyocellular environment (15) . Aside from their role as a metabolic substrate, FA are involved in a myriad of processes that ensure cellular growth and survival. FA also generate "lipid signals" that alter the cell's phenotype in response to extracellular stimuli. One such example is activation of nuclear transcriptional factors, such as peroxisome proliferator-activated receptors (PPARs), which increase the expression of proteins involved in fat metabolism in the face of enhanced FA delivery. Taken together, these observations indicate that the control of FA flux from intracellular lipid droplets is critical to maintain normal cell function (41) .
Lipolysis is controlled by the co-ordinate actions of several lipases and their interactions with lipid droplet-associated proteins (44) . Adipose triglyceride lipase (ATGL) is the major regulator of TAG lipolysis in most tissues, including skeletal muscle (11, 32, 39, 46) . The physiological importance of ATGL is highlighted by studies in Atgl Ϫ/Ϫ mice demonstrating reduced lipolysis, intracellular TAG accumulation, reduced FA oxidation, impaired exercise capacity, and cardiac failure leading to premature death (11, 14) . A growing body of evidence indicates that ATGL is also important in modulating mitochondrial function. Most prominently, ATGL generates essential lipid ligands for PPAR␣ activation in the heart, which is essential for maintaining mitochondrial FA oxidation, preventing myocardial lipid accumulation, and avoiding lethal cardiomyopathy (12) . Similarly, overexpressing ATGL in white adipose tissue promotes an "oxidative phenotype" in adipocytes, which is associated with increased FA oxidation, increased whole body energy expenditure, and resistance to diet-induced obesity (3) . Consistent with this notion, ATGLmediated lipolysis is required for maintaining normal brown adipose tissue (BAT) function, and ATGL deletion converts BAT, which is rich in mitochondria, to a tissue that more closely resembles white adipose tissue characterized by a low oxidative capacity (2) . ATGL deletion in the liver has a less pronounced impact on transcripts for mitochondrial biogenesis but resulted in decreased FA oxidation (36) . In skeletal muscle, deletion (14) or modest overexpression of ATGL (32) has no effect on the expression of key metabolic genes, mitochondrial content, or respiration. These tissue-specific effects of ATGL on cellular adaptation are perplexing, and this uncertainty is a major hurdle in moving forward with pharmacological strategies that manipulate ATGL function for metabolic disease (22) .
Emerging evidence indicates that skeletal muscle lipid droplet biology and mitochondrial metabolism are intimately linked (17) , although there is some debate in the field (21, 32) . We hypothesized that increasing lipolysis from intramyocellular lipid droplets would act as a molecular signal to increase mitochondrial biogenesis and FA oxidative capacity. To test the hypothesis, we overexpressed ATGL in cultured myotubes and murine skeletal muscle and examined molecular adaptations and FA metabolism.
METHODS
Cell culture studies. C2C12 myoblasts were grown in Dulbecco's Modified Eagle Medium (DMEM; GibcoLife Technologies, Mulgrave, VIC, Australia) (5 mmol/l glucose, 10% fetal bovine serum, 1% penicillin-streptomycin) until confluent and were differentiated into myotubes by changing the medium to DMEM with 2% horse serum. For overexpression studies, cells were infected on day 2 of differentiation with recombinant adenoviral vectors Ad-GFP [1.24 ϫ 10 8 plaque-forming units (pfu)/well] expressing enhanced green fluorescent protein (GFP) or Ad-ATGL (1.56 ϫ 10 8 pfu/well) expressing wild-type ATGL with GFP (fusion protein). The adenoviral vectors were produced and purified by Vector Biolabs (Philadelphia, PA). Experiments were performed 5 days after differentiation. For some experiments, myotubes were treated for 24 h with 125 M FA mixture (2:1 oleate-palmitate) conjugated to 0.5% FA-free bovine serum albumin (BSA) (Bovogen, Essenden, Victoria, Australia) or 1 M of the PPAR‫ץ‬ agonist CAY-10592 (Sapphire Bioscience, Waterloo, NSW, Australia) before lysing.
Mice studies. All experimental procedures were approved by the Monash University School of Biomedical Science Animal Ethics Committee and were conducted in accordance with the National Health and Medical Research Council of Australia's guidelines on animal experimentation. Male C57BL/6J mice aged 8 wk were purchased from Monash Animal Services (Clayton, Victoria, Australia). Mice were housed under controlled temperature (22°C) and lighting (12:12-h light-dark cycle) and had free access to water and standard rodent chow (Specialty Feeds irradiated rat and mouse pellets; 14.3 MJ/kg digestible energy). ATGL adenoassociated virus (AAV6-CMV-m-PNPLA2, 30 l, 5 ϫ 10 10 gene copies/ml) was directly injected into the right tibialis anterior (TA) muscle. An empty AAV vector (AAV6-CMV-Null, 30 l, 5 ϫ 10 10 gene copies/ml) was injected into the left tibialis anterior muscle and used as a control. Five weeks later, mice were fasted from 0700 -1100 and killed by cervical dislocation, and tissues were rapidly dissected for subsequent analysis. A portion of the TA was embedded in mounting media and frozen in thawing isopentane that was previously frozen in liquid nitrogen for subsequent immunohistochemistry. The remaining part of the TA was snap-frozen in liquid nitrogen. Because the AAV technique also results in vector expression in the extensor digitorum longus (EDL) muscle, which lies in close proximity to the TA muscle, the EDL was excised from tendon to tendon and used for FA metabolism experiments.
FA metabolism. To measure metabolism of exogenous FA, myotubes were incubated for 4 h with [1- 14 C]palmitate (0.5 Ci/ml; PerkinElmer, Boston, MA) and cold palmitate (0.5 mM), with 2% FA-free BSA in low-glucose DMEM. The ATGL inhibitor R-Bel (40 M) and hormone-sensitive lipase (HSL) inhibitor NNC76-0079 (NNC, 2 M) were added at the beginning of the experiment. In separate experiments to determine metabolism of intracellular sources of FA, myotubes were pulsed for 4 h with [1- 14 C]palmitate or [1-14 C]oleate (0.5 Ci/ml; PerkinElmer) and cold palmitate or oleate (0.5 mM), with 2% FA-free BSA in low-glucose DMEM. To determine the specific activity of the TAG pool, some cells were harvested at the end of the pulse (i.e., 0 time point, Fig. 1B ).
14 C-labeled FA incorporation in the TAG pool was assessed after thin-layer chromatography (TLC, see below), and the total TAG content was determined by biochemical analysis (GPO-PAP reagent; Roche Diagnostics). Following the pulse, myotubes were chased for 4 h in DMEM containing 2% FA-free BSA. The ATGL inhibitor R-Bel (40 M) and HSL inhibitor NNC (2 M) were added during the final hour of the pulse and during the chase periods. The production of 14 CO2 was measured in independent experiments that assessed TAG-derived (endogenous FA oxidation) and extracellular-derived FA oxidation.
In all experiments, myotubes were harvested in 0.6 ml PBS at the end of the pulse and chase periods to determine 14 C-FA incorporation into TAG and diglyceride and for assessment of protein content. The lipid extract was separated by TLC using heptane-isopropyletheracetic acid (60:40:3, vol/vol/vol) as developing solvent. All assays were performed in triplicate, and data were normalized to cell protein content.
Lipolysis. Myotubes were incubated in low-glucose DMEM for 3 h in the presence or absence of 1 M isoproterenol. Lipolysis was assessed by measuring glycerol release in the culture medium (Free Glycerol Reagent, F6428; Sigma).
Cellular bioenergetics. The cellular bioenergetics profile of myotubes was assessed using the Seahorse XF24 Flux Analyzer (Seahorse Bioscience). Myotubes were seeded into a 24-well XF24 cell culture microplate (Seahorse Bioscience) and were differentiated and infected with adenovirus as described above. Cells were washed and incubated in 600 l unbuffered DMEM (containing 5 mM glucose, 1 mM pyruvate, and 1 mM glutamate), pH 7.4, at 37°C in a non-CO 2 incubator (1 h before bioenergetics assessment). Three basal oxygen consumption rate measurements were performed using the Seahorse analyzer, and measurements were repeated following injection of oligomycin (1 M), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (1 M), and antimycin A (1 M). Basal extracellular acidification rate (glycolytic flux) was determined from data collected at basal measurement points. Calculations of respiratory parameters of mitochondrial function were performed as previously described (20) , and substrate oxidation was independently assessed. Briefly, for glucose oxidation assays, myotubes were incubated in Krebs buffer containing 25 mM glucose as the sole substrate for 60 min before the start of the assay, at 37°C for 60 min. These myotubes were coincubated with either vehicle (H2O) or 100 mM 2-deoxyglucose throughout this time period, and glucose oxidation was measured as the difference in oxygen consumption between vehicle and 2-deoxyglucose-treated myotubes. The parameters of the oxidation assays were based on the work by Wu et al. (42) , which showed that total substrate oxidation is not reduced, and in fact is enhanced, when cells are supplied with multiple substrates following acute exposure to 2-deoxyglucose of concentrations up to 200 mM. For palmitate oxidation assays, myotubes were incubated in Krebs buffer containing 0.25 mM palmitate as the sole substrate and were coincubated with vehicle (H2O) or 40 M etomoxir, and palmitate oxidation was measured as the difference between vehicle and etomoxir-treated myotubes.
Glycolysis was assessed using an independent, radiometric approach. Differentiated C2C12 myotubes were incubated in DMEM containing 5 mM glucose and 1 Ci/ml D- [3- 3 H]glucose (PerkinElmer) for 2 h. At the conclusion of the experiment, a portion of the medium was counted for total radioactivity, and another portion was incubated overnight at 60°C to evaporate the 3 H2O. Glycolysis was determined from the difference in radioactivity between the total and 3 H2O fractions.
Quantitative real-time PCR. Myotubes or TA muscle was homogenized in Qiazol, and total RNA was extracted. Reverse transcription of 1 g mRNA was performed (iScript cDNA Synthesis Kit; Bio-Rad Laboratories, Hercules, CA), and gene products were determined by quantitative real-time PCR (Realplex Mastercycler; Eppendorf) using the TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays for Pnpla2 (ATGL), Ppargc1a (PGC1␣), Cpt1b (CPT1b), Lpl (LPL), Pdk4 (PDK4), Plin2 (PLIN2), Ucp2 (UCP2), Dgat1 (DGAT), Gpat (GPAT), and Cd36 (CD36). The relative quantification was calculated using the ⌬⌬C t method, using 18S rRNA as the housekeeping gene, and values were normalized to the GFP-treated condition.
Immunoblot analysis. Myotubes and TA muscle were lysed in RIPA buffer containing 1 mM DTT, protease (complete Protease Inhibitor Cocktail; Roche Diagnostics, Castle Hill, NSW, Australia), and phosphatase (PhosSTOP Phosphatase Inhibitor Cocktail; Roche Diagnostics) inhibitors. Protein concentration was determined (Pierce BCA assay; Thermo Scientific, Rockford, IL), and equal amounts of lysate (20 g) were loaded into 10% Criterion precast stain-free gels (Bio-Rad Laboratories, NSW, Australia) and transferred to PVDF membranes (Trans-Blot Turbo Transfer System; Bio-Rad Laboratories). Stain-free blot images for total proteome visualization were obtained (ChemiDoc MP System; Bio-Rad Laboratories). The membranes were blocked with 5% milk, washed, and probed with antibodies raised against ATGL (no. 2138; Cell Signaling), OXPHOS (Mitoprofile, total OXPHOS rodent WB antibody cocktail, MS604), phospho-acetyl-CoA carboxylase (ACC) Ser 79 (no. 3661; Cell Signaling), ACC (C83B10) (no. 3676; Cell Signaling), phospho-AMP activated protein kinase (AMPK) Thr 172 (no. 2535; Cell Signaling), and AMPK (no. 2532; Cell Signaling). After being washed, membranes were probed with the appropriate secondary antibody (antirabbit IgG; GE Healthcare). Bands were detected with enhanced chemiluminescence (Clarity Western ECL Substrate; Bio-Rad Laboratories) using the Chemidoc (ChemiDoc MP System; Bio-Rad Laboratories) and quantified by densitometry (ImageLab, version 4.1; BioRad). The immunoreactive signal was normalized to the density of the total protein loading for each sample, which was obtained by visualization of the stain-free blot image and quantified using ImageLab.
PPAR␣/Ѩ activity. PPAR␣/‫ץ‬ activity was determined in whole cell lysates from myotubes using a commercially available ELISA Immunohistochemistry. Serial 10-m sections were cut at Ϫ20°C on SuperFrost Ultra Plus glass slides. Slides were fixed in Bouin's solution with 0.1% Triton X-100 (Sigma-Aldrich) for 1 h and then rinsed 3 ϫ 5 min in PBS. Sections were blocked in PBS with 1% BSA for 1 h and then incubated overnight with ATGL antibody (ϳ0.02 mg/ml). For negative controls, primary antibody was substituted for concentration-matched mouse IgG2a for ATGL (Dako) antibodies. Following a further 3 ϫ 5 min wash with PBS, secondary Alexa Fluor antibodies (Life Technologies) were incubated for 1 h at room temperature. Slides were washed for 3 ϫ 10 min with PBS before being covered with cover slips with mounting media containing DAPI (catalog no. H-1500; Vector Laboratories, Burlingame, CA). Images were captured using a Zeiss microscope (Zeiss, Oberkochen, Germany) with an AxioCam MR camera using DAPI UV (340 -380 nm) and FITC (465-495 nm) excitation filters.
Succinate dehydrogenase staining. Sections were incubated at 37°C for 8 min in 0.2 M phosphate buffer containing sodium succinate (catalog no. S2378; Sigma-Aldrich) and nitro blue tetrazolium (catalog no. N5514; Sigma-Aldrich). Sections were washed in water, treated with increasing concentrations of acetone, rinsed, and mounted (catalog no.36226S; Gurr Microscopy Materials, BDH, Poole, UK). Images were captured using a Zeiss microscope.
Mitochondrial enzyme activity. TA muscle (ϳ10 mg) was homogenized in ice-cold buffer containing 0.1 M KH 2PO4 and 0.05% BSA, pH 7.3 (50 l buffer/mg wet weight), and subjected to two freeze thaw cycles. The supernatant was used to determine citrate synthase and ␤-hydroxyacyl-CoA dehydrogenase activity by enzymatic spectrophotometric analysis (19, 33) .
Statistical analysis. Data are reported as means Ϯ SE. To examine differences between control and ATGL-infected cells or muscle, data were analyzed with unpaired and paired t-tests, respectively. Statistical significance was determined a priori at P Ͻ 0.05.
RESULTS
Flux through the intramyocellular TAG pool regulates whole cell FA oxidation. Studies using isotope methodologies in humans demonstrate that a large proportion of the free fatty acids (FFA) that are oxidized by skeletal muscle must first traffic through the intramyocellular TAG pool (15, 29, 45) . Because of the inherent technical limitations of this technique in determining the specific source of FA draining into the venous circulation (9), we examined intramyocellular FA flux in cultured C 2 C 12 myotubes by combining radiolabeled substrate techniques with pharmacological ATGL and HSL inhibitors (R-Bel and NNC, respectively). Cells were pulsed with 14 C]TAG pool was depleted by 60% in the control myotubes at the end of the chase period, whereas the [ 14 C]TAG pool in the presence of R-Bel ϩ NNC was reduced by only 28% (Fig. 1A) . The reduction in net TAG breakdown was associated with a 40% decrease in the oxidation of TAGderived FA in R-Bel ϩ NNC-treated myotubes compared with control ( Fig. 1, B and C) . Consistent with the reduction in FA oxidation, the amount of radiolabel remaining in the TAG pool was increased in R-Bel ϩ NNC-treated myotubes compared with control (Fig. 1B) . Hence, blocking ATGL and HSL activities reduces TAG-derived FA release and oxidation.
We next tested whether acute lipase inhibition reduces the oxidation of extracellular-derived 14 C-FA (which represent plasma FA in vivo). FA uptake into myotubes was similar between control and R-Bel ϩ NNC-treated myotubes (Fig.  1D ). The rate of FA incorporation into TAG under control conditions was 74 Ϯ 15 pmol·mg Ϫ1 ·min Ϫ1 , and this was increased by 60% in R-Bel ϩ NNC-treated myotubes compared with control (Fig. 1D) . The basal rate of FA incorporation into diglycerides under control conditions was 17 Ϯ 2 pmol·mg Ϫ1 ·min Ϫ1 , and this was not altered with R-Bel ϩ NNC treatment (Fig. 1D) . The basal rate of extracellular-derived FA oxidation (4.0 Ϯ 0.9 pmol·mg Ϫ1 ·min Ϫ1 ) was remarkably similar to that of intracellular-derived FA oxidation (3.2 Ϯ 0.9 pmol·mg Ϫ1 ·min Ϫ1 ) under control conditions. As was observed with the assessment of intracellular FA metabolism, the oxidation of extracellular-derived FA was reduced by 40% in R-Bel ϩ NNC-treated myotubes compared with control ( Fig.  1, D and E) . Taken together, these data demonstrate that a large proportion of the FA that are transported into myotubes are first trafficked through the intramyocellular TAG pool before their eventual oxidation (Fig. 1E) .
ATGL overexpression increases intramyocellular TAG turnover. To test whether ATGL enhances trafficking out of the intramyocellular TAG pool, we increased ATGL content using a recombinant adenoviral vector. ATGL mRNA expression ( Fig. 2A ) and protein content (Fig. 2, B and C) were increased by ATGL adenovirus compared with the GFP adenovirus. Expression was variable in individual myotubes as demonstrated by the intensity of GFP staining (Fig. 2D) . Glycerol release into the culture media represents lipolysis and was undetectable in Ad-GFP myotubes and readily detectable in Ad-ATGL myotubes under basal state conditions (Fig. 2E) . Glycerol release was increased in both groups upon ␤-adrenergic stimulation but remained higher in Ad-ATGL compared with Ad-GFP (Fig. 2E) . The uptake and oxidation of FA derived from the culture medium were not different, whereas less FA was trafficked into TAG and diglyceride with ATGL compared with GFP overexpression (Fig. 2F) , suggesting reduced esterification or, most likely, increased lipolysis with ATGL overexpression. We tested these possibilities by examining the oxidation of FA derived from intracellular stores. Myotubes were preloaded with [
14 C]oleate for 6 h, washed thoroughly to remove extracellular [ 14 C]oleate, and then assessed for fatty oxidation. FA oxidation derived from intracellular lipid stores was increased by 51% in ATGL-vs. GFPoverexpressing cells, and this was associated with a decrease in the [
14 C]oleate contained in TAG and diglycerides (Fig. 2G ). Because ϳ80% of the radioactivity within the intramyocellular lipid pool was contained in glycerolipids (data not shown), and degradation of phospholipids contributes minimally to cellular FA oxidation, we consider this to be representative of TAGderived FA oxidation. Notably, GFP-overexpressing myotubes formed an abundance of TAG-rich lipid droplets upon acute lipid loading, as demonstrated by Oil Red O staining, whereas ATGL-overexpressing myotubes were largely devoid of distinct intracellular lipid droplets (Fig. 2D) . The capacity for FA esterification into glycerolipids was unlikely to be impaired because glycerol-3-phosphate acyltransferase and diglyceride acyltransferase expression was actually increased in ATGLoverexpressing myotubes compared with Ad-GFP (Fig. 2H) .
Together, these data demonstrate that ATGL overexpression increases TAG turnover in myotubes.
ATGL overexpression activates a subset of PPAR␣/Ѩ target genes and promotes Ppargc1a expression.
Restoring ATGL function in ATGL null mice activates a subset of PPAR␣ target genes to restore mitochondrial function in the heart (12) . While ATGL null mice have normal mitochondrial capacity and function in skeletal muscle (13, 26) , we hypothesized that ATGL-mediated FA turnover would provide a ligand(s) to enhance PPAR-mediated signaling and enhance mitochondrial function. ATGL overexpression in myotubes increased a subset of known PPAR␣/‫ץ‬ genes (6), including Cpt1b, Lpl, Pdk4, and Plin2 (Fig. 3A) . ATGL overexpression also increased the expression of Ppargc1a (Fig. 3B) , a transcriptional coactivator of mitochondrial biogenesis.
We next tested whether a generalized increase in FA availability, independent of increased ATGL content, would increase the same subset of PPAR target genes. FA uptake rates into myotubes were similar between Ad-GFP and Ad-ATGL (Fig. 3C) . FA treatment did not affect PPAR target genes or Ppargc1a expression in GFP-overexpressing cells (Fig. 3D) . Similarly, the ATGL-mediated changes in gene expression with increasing amounts of adenovirus and no effect on endogenous ATGL protein content (54 kDa). Arrow denotes nonspecific bands. C: ATGL-GFP and protein content quantified from myotubes infected with 4.1 ϫ 10 12 vp/ml (n ϭ 3 Ad-GFP, n ϭ 5 Ad-ATGL). D: Oil Red O staining demonstrates reduced lipid droplet number and density in myotubes infected with Ad-ATGL compared with Ad-GFP. Green staining, enhanced GFP (eGFP) from adenovial infection; blue staining, DAPI staining on nuclei. E: glycerol release into the culture medium (n ϭ 4/column). F: FA uptake, FA oxidation, and FA incorporation of extracellular-derived FA into intracellular TAG and DAG in myotubes (n ϭ 9 -11/column obtained from 3 independent experiments). Schematic on top shows the experimental design. G: pulse-chase experiments were used to assess the oxidation of FA derived from intracellular-derived lipids and the 14 C-FA remaining in intracellular TAG and DAG (n ϭ 12/column derived from 3 individual experiments). Schematic on top shows the experimental design. H: Dgat1 and Gpat expression in myotubes. vp, Viral particles. *P Ͻ 0.05 vs. Ad-GFP.
were not altered by FA treatment, suggesting that increasing FA flux into the myotubes per se is insufficient to modulate the same transcriptional program as the ATGL-mediated lipid flux.
Because ATGL overexpression appeared to provide an environment capable of increasing PPAR target genes, we assessed PPAR␣/‫ץ‬ activity in cell lysates. PPAR␣ activity was not different between treatments (data not shown), whereas PPAR‫ץ‬ activity was marginally increased in ATGL-compared with GFP-overexpressing cells (Fig. 3E) . We also tested whether the ATGL-mediated gene expression changes overlapped with transcriptional alterations induced by a highly specific PPAR‫ץ‬ receptor agonist, CAY10592. There was no consistency in gene expression changes induced by ATGL and CAY10592, suggesting that the changes in gene expression by ATGL overexpression are not exclusively acting through PPAR‫ץ‬ (Fig. 3F) . Moreover, CAY10592 increased the expression of some genes (Cpt1b, Pdk4) but not others (Lpl, Plin2, Ppargc1a) in ATGL-overexpressing myotubes (data not shown), providing further support for the interpretation that ATGL overexpression induces changes in gene expression independent of PPAR‫.ץ‬ ATGL overexpression enhances mitochondrial capacity. The notion that ATGL overexpression enhances mitochondrial capacity was supported by increased expression of respiratory chain proteins (Fig. 4A) . We directly assessed mitochondrial function by measuring cellular respiration in the myotubes. Both basal and maximal respiration was increased in ATGLcompared with GFP-overexpressing cells (Fig. 4, B and C) . When using the Seahorse Flux Analyzer, quantitative measures of specific substrates are complicated by the utilization of both extracellular (glucose or FFA added to the culture medium) and intracellular (both TAG-derived FA and glycogen-derived glucose) fuels. Therefore, we assessed total glucose oxidation by subtracting total glucose oxidation from 2-deoxyglucoseinsensitive oxidation (which measures oxidation from sources other than glucose). Glucose accounted for ϳ90% of the total substrate oxidized (data not shown), and glucose oxidation was not different between Ad-ATGL-vs. Ad-GFP-expressing myotubes (12% difference, P ϭ 0.28) (Fig. 4D) . Similarly, a small, nonsignificant (7%, P ϭ 0.07) increase in FA oxidation was observed in Ad-ATGL myotubes (Fig. 4D) . The extracellular acidification rate (i.e., glycolysis) was increased in ATGLoverexpressing myotubes (Fig. 4E) . This result was confirmed using an independent radiometric approach (Ad-GFP: 1.01 Ϯ 0.01 vs. Ad-ATGL: 1.15 Ϯ 0.03 nmol·mg protein Ϫ1 ·h Ϫ1 , P ϭ 0.0001). Collectively, these data demonstrate a mild increase in energy turnover in Ad-ATGL myotubes. The increased substrate oxidation was associated with increased phosphorylation of 5=-AMPK at Thr 172 (Fig. 4F) . Phosphorylation of the AMPK substrate ACC␤ Ser 221 was increased by 275% (Fig. 4 , G and H), but failed to reach statistical significance when expressed relative to ACC␤, which is due to an increase in total ACC␤ protein content (ϩ140%).
In vivo overexpression of ATGL promotes moderate changes in skeletal muscle and does not enhance FA oxidation. To explore the role of ATGL on molecular adaptations in skeletal muscle in vivo, we injected an AAV-containing Pnpla2 (ATGL) into the TA muscle of one leg and an AAV-containing enhanced GFP in the contralateral TA of mice. The AAV increased ATGL mRNA (Fig. 5A) and protein content (Fig. 5,  B and C) by ϳ20-fold above the AAV-and GFP-injected leg. ATGL protein content was also increased by ϳ15-fold in the EDL muscle (data not shown). Immunohistochemistry showed that the AAV targeted the vast majority of myofibers (Fig. 5D) . ATGL overexpression induced modest effects in skeletal muscle. Expression of genes encoding proteins involved in lipid metabolism tended to increase (Fig. 5E) , there was a tendency for several respiratory complex proteins to increase (Fig. 5F) , and succinate dehydrogenase content was increased (Fig. 5G) . The maximal activity of citrate synthase, a regulator of tricarboxylic acid cycle flux, was increased with ATGL overexpression (Fig. 5H) , whereas the maximal activity of the ␤-oxidation enzyme ␤-hydroxyacyl CoA-dehydrogenase was not changed (Fig. 5I) . Functionally, ATGL overexpression resulted in a reduction of radiolabeled FA incorporation into the TAG pool (Fig. 5J) , with no change in FA oxidation (Fig. 5K) . Consistent with our results in cultured myotubes, ATGL overexpression increased AMPK and ACC␤ protein contents (Fig. 5, L and  M) . Altogether, marked ATGL overexpression induced modest molecular changes in skeletal muscle, but these were not sufficient to alter FA oxidation.
DISCUSSION
The skeletal muscle is subjected to extraordinary metabolic challenges that include pronounced increases in energy turnover during high-intensity activity and the requirement for sustained increases in substrate oxidation and ATP production during prolonged physical exertion. Accordingly, skeletal muscle exhibits remarkable plasticity by responding to mechanical and metabolic stress signals that in turn activate transcriptional programs to enhance the capacity of the tissue to deal with future metabolic insults (8) . FA are ligands for nuclear transcription factors involved in metabolic reprogramming (25) , and increasing FA delivery to skeletal muscle through dietary interventions (35) or lipid infusions (7, 23) increases the capacity for FA oxidation. The goal of this study was to determine whether increasing FA flux from intramyocellular TAG by ATGL overexpression is sufficient to induce metabolic adaptations within muscle. Our findings show that ATGL overexpression is sufficient to reprogram skeletal muscle and alter mitochondrial capacity in cultured myotubes in vitro but that ATGL overexpression does not induce marked changes in molecular programming of the skeletal muscle metabolic phenotype in vivo.
A large proportion of the plasma-derived FFA taken up by skeletal muscle is first trafficked into intramyocellular TAG before they are released and enter the long-chain acylcarnitine pools for oxidation (5, 15, 29) . These data suggest that the lipid droplet is a central control point for intramyocellular FA flux. A technical limitation of these in vivo approaches using arteriovenous balance techniques in humans is that the specific source of FA draining into the venous circulation cannot be determined because FA can be generated from lipolysis of intramyocellular TAG droplets, intramuscular adipocytes residing within muscle groups, or intermuscular adipocytes residing between muscle groups (10) . Examining FA flux in cultured myotubes circumvents these limitations. Hence, the first aim of this study was to determine whether FA first traverse the intramyocellular TAG pool before undergoing lipolysis to be released from the lipid droplet for oxidation or other actions within myocytes. Our pulse-chase studies in cultured myotubes show that pharmacological inhibitors of ATGL and HSL reduce intracellular TAG lipolysis and the oxidation of FA derived from intramyocellular sources. Critically, when radiolabeled FA are added to the culture medium (i.e., representing "plasma"-derived FA), ATGL and HSL inhibition increases radioactivity in the intramyocellular TAG pool and decreases FA oxidation. The reduction in FA oxidation with ATGL and HSL inhibition was proportionally the same whether derived from intracellular or extracellular sources. These data support previous reports in humans showing that FA are first entering the TAG pool before being released and oxidized. A limitation of this approach is that we cannot conclude with absolute certainty that the FA entering the myotubes are traversing an intracellular pool other than TAG, before oxidation. However, a major involvement of another lipid pool is unlikely given the relatively low incorporation of FA into lipid pools other than TAG before oxidation [212 disintegrations·min Ϫ1 (dpm)·well Ϫ1 ] compared with the enrichment in TAG (918 dpm/well) and the subsequent oxidation rates (619 dpm/well).
To determine whether increasing lipolysis from intramyocellular lipid droplets acts as a molecular signal to increase mitochondrial and FA oxidative capacity, we first overexpressed ATGL in myotubes in vitro. ATGL is the major TAG lipase in muscle, and adenoviral-mediated ATGL overexpression increased lipolysis and the expression of several genes involved in FA metabolism. ATGL overexpression increased PPAR‫ץ‬ activity, albeit mildly, which is consistent with the notion that FA activate PPAR‫ץ‬ transcriptional activity (16) . It is possible that lipid ligands other than FA could mediate this effect, as has been proposed in the heart (12) . It is also likely that factors other than PPAR‫ץ‬ contributed to the changes in gene expression because not all PPAR‫ץ‬ target genes examined were increased, and the effects of ATGL expression did not reproduce the transcriptional responses induced by a highly specific PPAR‫ץ‬ agonist. PPAR␣ does not appear to be a major target of ATGL-mediated changes in skeletal muscle, which contrasts findings in hepatocytes, brown adipose tissue, and intestinal cells (24, 27, 31) . Finally, the gene expression changes induced by ATGL overexpression were not reproduced when FA were added to the culture medium, suggesting that ATGL-mediated alterations in transcriptional activity are not solely attributed to an increase in FA delivery per se. This latter finding is consistent with data from islet ␤-cells (34) . In this study, FA added to ␤-cells isolated from wild-type mice promoted insulin secretion, whereas the addition of FA to ␤-cells isolated from ATGL knockout mice did not cause an increase in insulin release, suggesting that exogenous FA cannot simply substitute for ATGL-induced lipolysis (34) . Another contributor to the increase in oxidative capacity could be the increase in energy expenditure following ATGL overexpression, which was characterized by subtle increases in basal oxygen consumption, glycolysis, AMPK activation, and nonsignificant increases in glucose (23%) and FA (7%) oxidation. How ATGL increases energy expenditure is unknown at this point but could involve futile cycles of lipolysis/reesterification that subsequently results in greater flux through a number of pathways that contribute to ATP generation. The increased oxidative capacity could be a direct response to increased flux through these pathways. Together, our findings show that increasing TAG flux from intramyocellular lipid droplets impacts several processes to alter the transcription of metabolic genes in myotubes.
Consistent with the changes in gene expression, ATGL overexpression also increased PGC1␣ gene expression, a regulator of mitochondrial biogenesis (28) , as well as the protein contents of several components of the respiratory chain. Mitochondrial function was similarly impacted by ATGL overexpression with increased basal and maximal respiration rates. These results demonstrate that an increase in ATGL can increase the oxidative capacity of myotubes, although the importance of ATGL to promote mitochondrial function has been shown to be more prominent in other cell types (1, 34) . In macrophages, for example, knock down of ATGL resulted in intracellular steatosis, mitochondrial dysfunction, and programmed cell death (1) . Similarly, in pancreatic ␤-cells, deletion of ATGL decreased the expression of PPAR␦ target genes involved in mitochondrial oxidation, and coincided with impaired mitochondrial respiration. Adenoviral overexpression of ATGL restored these mitochondrial defects in pancreatic ␤-cells and normalized glucose-stimulated insulin secretion (34) . Together, these findings confirm the importance of ATGL for maintaining mitochondrial function in skeletal muscle and other cell types in vitro.
Skeletal muscle ATGL content is upregulated ϳ2.5-fold by regular endurance exercise training in humans (4), suggesting that FA flux through the lipid droplet may contribute to transcriptional reprogramming. On the other hand, it was previously shown that ATGL transgenic mice harboring a 1.5-fold increase in ATGL protein content above wild-type mice exhibited a small reduction in intramyocellular TAG and no change in mitochondrial content or function (32) . In light of these contrasting observations, we surmised that germ line alterations in ATGL function might induce compensatory molecular regulation in mice and/or a robust increase in ATGL, above the modest 1.5-fold reported previously in transgenic mice (32) , is required to drive metabolic reprogramming. To overcome these issues, we increased ATGL in the skeletal muscle of adult mice by AAV-ATGL administration, which increased ATGL content 20-fold. While there was an increase in intramyocellular TAG turnover and the expression of several PPAR␦ target genes, the effect on markers of mitochondrial content and capacity was modest and insufficient to drive changes in FA oxidation. Thus, we conclude that, in contrast to isolated myotubes, marked increases in ATGL expression are not a major factor in regulating mitochondrial function in skeletal muscle in vivo. It is likely that other transcriptional programs that are driven by contraction and energy-sensing signaling pathways or alterations in neural inputs or the endocrine milieu override the effects of ATGL overexpression in vivo.
Our studies add to previous work highlighting the tissuespecific importance of ATGL in metabolic regulation. In adipose tissue, for example, there is convincing evidence to show that ATGL is critical for fasting energy homeostasis. Fasting in combination with a deficiency of ATGL resulted in a progressive reduction of oxygen consumption, reduced FA availability for energy production, lethargy, hypothermia, and a proteolytic stress on many organs, including the heart and skeletal muscle (43) . On the other hand, a three-to fivefold overexpression of ATGL in adipose tissue promoted FA oxidation and attenuated diet-induced obesity (3). In brown adipose tissue, ATGL is required to maintain thermogenic capacity by providing FA substrate for uncoupled respiration (2) , and, in the heart, ATGL is required to maintain mitochondrial function via PPAR␣-related programming (12) . Thus, while ATGL might be less important in regulating metabolic adaptations that promote mitochondrial function in skeletal muscle (present data and Refs. 14 and 26), it is clearly a major regulator of these events in other tissues.
The implications of this work relate to understanding lipid fluxes in muscle and understanding strategies to combat metabolic complications. The in vitro studies support previous human work showing that a large proportion of FA that enter muscle are first stored in lipid droplets before their eventual oxidation. Furthermore, our findings demonstrate that enhancing FA flux from lipid droplets can remodel myotubes to increase the transcriptional program to drive mitochondrial capacity, which enhances oxidative capacity and reduces the lipid content in vitro. However, this adaptive program is of minor importance when superimposing the normal metabolic stresses encountered in free-moving animals, indicating that, unlike other tissues such as the heart and adipose tissue, ATGL overexpression is of minor importance in the remodeling skeletal muscle to enhance the oxidative disposal of FA. 
